Critical Outcome Technologies Inc. (COTI)
TSX VENTURE : COT
OTCQB : COTQF

Critical Outcome Technologies Inc. (COTI)

October 06, 2014 09:00 ET

Critical Outcome Technologies to Present at 13th Annual BIO Investor Forum on Tuesday, October 7, 2014

Significant Impact of COTI-2's p53-dependent Mechanism of Action on Cancer to Be Highlighted

LONDON, ONTARIO--(Marketwired - Oct. 6, 2014) - Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENUTRE:COT)(OTCQB:COTQF), the bioinformatics and accelerated drug discovery company, announced today that Dr. Wayne Danter, President and Chief Executive Officer, will be presenting at the 13th Annual BIO Investor Forum being held October 7-8, 2014 at the Palace Hotel in San Francisco, California. The annual Bio Investor Forum is hosted by the Biotechnology Industry Organization (BIO) and features leading private and emerging public companies.

Dr. Danter is scheduled to present on Tuesday, October 7, 2014, at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time) in the Sea Cliff Room at the Palace Hotel. In addition to providing an overview of the Company, Dr. Danter's presentation will focus on the Company's lead cancer drug candidate, COTI-2, which has a p53-dependent mechanism of action and which recently received the Orphan Drug Designation from the United States Food and Drug Administration for the treatment of ovarian cancer.

The presentation will be available on the Company's blog at www.criticaloutcomeblog.com/blog-posts and on SlideShare at www.slideshare.net/CriticalOutcome.

About Critical Outcome Technologies Inc.

COTI is a leading-edge bioinformatics company specializing in accelerating the discovery and development of small molecules - dramatically reducing the time and cost to bring new drugs to market. COTI's proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome

Contact Information